175 related articles for article (PubMed ID: 32303488)
1. Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities.
Sallman DA; Barnard J; Al Ali NH; Garcia-Manero G; Sekeres MA; DeZern A; Steensma DP; Roboz G; Jabbour E; Maciejewski JP; Pierce S; Padron E; Lancet JE; Kantarjian H; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e597-e605. PubMed ID: 32303488
[TBL] [Abstract][Full Text] [Related]
2. Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities.
Wanquet A; Prebet T; Berthon C; Sebert M; Roux C; Kulasekararaj A; Micol JB; Esterni B; Itzykson R; Thepot S; Recher C; Delaunay J; Dreyfus F; Mufti G; Fenaux P; Vey N
Am J Hematol; 2015 Oct; 90(10):859-63. PubMed ID: 26113240
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
4. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
Jabbour EJ; Garcia-Manero G; Strati P; Mishra A; Al Ali NH; Padron E; Lancet J; Kadia T; Daver N; O'Brien S; Steensma DP; Sekeres MA; Gore SD; Dezern A; Roboz GJ; List AF; Kantarjian HM; Komrokji RS
Cancer; 2015 Mar; 121(6):876-82. PubMed ID: 25410759
[TBL] [Abstract][Full Text] [Related]
5. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.
Sébert M; Komrokji RS; Sekeres MA; Prebet T; Cluzeau T; Santini V; Gyan E; Sanna A; Ali NH; Hobson S; Eclache V; List A; Fenaux P; Adès L
Leuk Res; 2017 Dec; 63():72-77. PubMed ID: 29112938
[TBL] [Abstract][Full Text] [Related]
6. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.
Schanz J; Tüchler H; Solé F; Mallo M; Luño E; Cervera J; Granada I; Hildebrandt B; Slovak ML; Ohyashiki K; Steidl C; Fonatsch C; Pfeilstöcker M; Nösslinger T; Valent P; Giagounidis A; Aul C; Lübbert M; Stauder R; Krieger O; Garcia-Manero G; Faderl S; Pierce S; Le Beau MM; Bennett JM; Greenberg P; Germing U; Haase D
J Clin Oncol; 2012 Mar; 30(8):820-9. PubMed ID: 22331955
[TBL] [Abstract][Full Text] [Related]
7. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
Ravandi F; Issa JP; Garcia-Manero G; O'Brien S; Pierce S; Shan J; Borthakur G; Verstovsek S; Faderl S; Cortes J; Kantarjian H
Cancer; 2009 Dec; 115(24):5746-51. PubMed ID: 19795507
[TBL] [Abstract][Full Text] [Related]
8. Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts.
Baek DW; Lee YJ; Kim H; Ahn SY; Ahn JS; Shin HJ; Lee WS; Lee SM; Song IC; Lee HS; Park SW; Choi Y; Cho YY; Bae SH; Kim HJ; Sohn SK; Moon JH
Ann Hematol; 2018 Dec; 97(12):2309-2317. PubMed ID: 30073392
[TBL] [Abstract][Full Text] [Related]
9. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
[TBL] [Abstract][Full Text] [Related]
10. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop.
Bloomfield CD; Archer KJ; Mrózek K; Lillington DM; Kaneko Y; Head DR; Dal Cin P; Raimondi SC
Genes Chromosomes Cancer; 2002 Apr; 33(4):362-78. PubMed ID: 11921271
[TBL] [Abstract][Full Text] [Related]
11. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
12. Retrospective evaluation of the clinical and laboratory data from 300 patients of various hematological malignancies with chromosome 3 abnormalities.
Liu D; Zhang Y; Chen S; Pan J; He X; Liang J; Chen Z
Cancer Genet; 2015 Jun; 208(6):333-40. PubMed ID: 26032184
[TBL] [Abstract][Full Text] [Related]
13. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop.
Andersen MK; Larson RA; Mauritzson N; Schnittger S; Jhanwar SC; Pedersen-Bjergaard J
Genes Chromosomes Cancer; 2002 Apr; 33(4):395-400. PubMed ID: 11921273
[TBL] [Abstract][Full Text] [Related]
14. Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine.
Li X; Chang C; He Q; Xu F; Zhang Q; Wu L; Su J; Zhang X; Zhou L; Wu D; Song L; Zhang Z
Leuk Res; 2013 Nov; 37(11):1516-21. PubMed ID: 24084368
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.
Short NJ; Jabbour E; Naqvi K; Patel A; Ning J; Sasaki K; Nogueras-Gonzalez GM; Bose P; Kornblau SM; Takahashi K; Andreeff M; Sanchez-Petitto G; Estrov Z; Dinardo CD; Montalban-Bravo G; Konopleva M; Alvarado Y; Bhalla KN; Fiskus W; Khouri M; Islam R; Kantarjian H; Garcia-Manero G
Am J Hematol; 2019 Jan; 94(1):74-79. PubMed ID: 30328139
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.
Solé F; Luño E; Sanzo C; Espinet B; Sanz GF; Cervera J; Calasanz MJ; Cigudosa JC; Millà F; Ribera JM; Bureo E; Marquez ML; Arranz E; Florensa L
Haematologica; 2005 Sep; 90(9):1168-78. PubMed ID: 16154839
[TBL] [Abstract][Full Text] [Related]
17. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
18. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of Cytogenetic Characteristics and Clinical Prognosis in 236 Patients with Myelodysplastic Syndrome].
Xia JY; Wang Y; Li DP; Li ZY; Qiu TT; Xu KL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1190-1195. PubMed ID: 31418378
[TBL] [Abstract][Full Text] [Related]
20. No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome.
Sohn SK; Moon JH; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Park SW; Lee WS; Lee SM; Kim H; Lee HS; Kim YS; Cho YY; Bae SH; Lee JH; Kim SH; Song IC; Kwon JH; Lee YJ
Korean J Intern Med; 2018 Nov; 33(6):1194-1202. PubMed ID: 29232940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
